The stock of gene therapy innovator REGENXBIO (RGNX) skyrocketed by a remarkable 15.2% on March 5, following the release of encouraging interim results from the phase I/II AFFINITY DUCHENNE study. The study focused on RGX-202, a one-shot gene therapy developed by REGENXBIO, designed to address Duchenne muscular dystrophy (DMD).
Game-Changing Improvements in Strength and Functionality
The groundbreaking data from the AFFINITY DUCHENNE study unveiled notable enhancements in strength and motor function among DMD patients treated with RGX-202. Astonishingly, no serious adverse effects were reported in patients aged four to 12 years who received doses at both level 1 and level 2.
Paving the Way for Regulatory Approval
Notably, all four patients treated with RGX-202 exhibited promising elevations in microdystrophin expression levels, along with marked reductions in serum CK levels after undergoing three months of gene therapy infusion. The management at REGENXBIO plans to leverage these compelling findings to expedite the commencement of a pivotal study before the culmination of the year.
Industry Comparison and Competitive Landscape
The surge in REGENXBIO’s shares, escalating by an impressive 37.1% year-to-date, overtakes the industry’s modest 2.8% rise. This highlights the company’s exceptional performance in the gene therapy sector, especially in contrast to competitors like Sarepta Therapeutics and Solid Biosciences.
The Race for DMD Treatment Innovation
Solid Biosciences, another key player in the DMD treatment arena, has been making significant strides in developing SGT-003, a potential gene therapy solution. Following the FDA’s clearance for clinical studies last year, Solid Biosciences is steadily progressing towards initiating a phase I/II study for DMD patients, aiming to replicate the success witnessed by REGENXBIO.
Investors Take Notice of a Rising Star
Despite this, REGENXBIO’s groundbreaking results have undoubtedly caught the attention of investors and industry analysts alike. With promising prospects on the horizon, the company is poised for further growth and success, propelling it to the forefront of the gene therapy landscape.
Zacks Rank & A Key Pick
In the midst of this dynamic environment, REGENXBIO maintains a Zacks Rank #3 (Hold). However, within the broader healthcare sector, ADMA Biologics emerges as a standout choice with a Zacks Rank #1 (Strong Buy). The surge in ADMA’s stock, coupled with favorable estimates, underscores the growing potential of innovative healthcare solutions.
Exploring Opportunities and Embracing Potential
As the landscape of gene therapy continues to evolve and expand, companies like REGENXBIO, Sarepta Therapeutics, and Solid Biosciences are at the forefront of revolutionizing the healthcare industry. With each milestone and breakthrough, the potential to transform lives and offer hope to patients battling rare diseases becomes increasingly tangible.
Only $1 to See All Zacks’ Buys and Sells
We’re not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.
Thousands have taken advantage of this opportunity. Thousands did not – they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more. They’ve already closed 162 positions with double- and triple-digit gains in 2023 alone.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
